Ayako Takenouchi1,2, Kengo Saito1, Eriko Saito1,2, Takeshi Saito2, Tomoro Hishiki2, Tadashi Matsunaga2, Naohisa Isegawa3, Hideo Yoshida2, Naomi Ohnuma2, Hiroshi Shirasawa4. 1. Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba, 260-8670, Japan. 2. Pediatric Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba, 260-8670, Japan. 3. Laboratory Animal Center, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba, 260-8670, Japan. 4. Molecular Virology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba, 260-8670, Japan. sirasawa@faculty.chiba-u.jp.
Abstract
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers. The SINV AR339 strain is blood borne and relatively non-virulent. We evaluated the feasibility of SINV AR339 for treating human NB. METHODS: The cytotoxicity and viral growth of SINV AR339 were evaluated for five human NB cell lines, SK-N-SH, IMR-32, LAN-5, GOTO, and RT-BM-1. SINV-induced apoptosis was confirmed by TUNEL assays and PARP-1 cleavage. In vivo effects of SINV on neuroblastoma cell xenografts in nude mice were assessed by intratumoral or intravenous SINV inoculation. RESULTS: In five human NB cell lines, SINV infections induced remarkable cytotoxicity. The mRNA expressions of anti-apoptotic genes, Bcl-2 and Bcl-xL, in LAN-5 and RT-BM-1, which were less sensitive to SINV infection, increased in response to SINV infection, while the other NB cell lines sensitive to SINV infection failed to respond. In nude mice, intratumoral and intravenous SINV inoculations caused significant regression of NB xenograft tumors. CONCLUSION: Our results suggested that SINV AR339 was significantly oncolytic against human NB. Thus, SINV showed promise as a novel therapy for treating NB.
PURPOSE: With current treatment regimens, high-risk neuroblastoma (NB) remains largely incurable. Oncolytic viral therapy uses replication-competent viruses, like Sindbis virus (SINV), to kill cancers. The SINV AR339 strain is blood borne and relatively non-virulent. We evaluated the feasibility of SINV AR339 for treating human NB. METHODS: The cytotoxicity and viral growth of SINV AR339 were evaluated for five human NB cell lines, SK-N-SH, IMR-32, LAN-5, GOTO, and RT-BM-1. SINV-induced apoptosis was confirmed by TUNEL assays and PARP-1 cleavage. In vivo effects of SINV on neuroblastoma cell xenografts in nude mice were assessed by intratumoral or intravenous SINV inoculation. RESULTS: In five human NB cell lines, SINV infections induced remarkable cytotoxicity. The mRNA expressions of anti-apoptotic genes, Bcl-2 and Bcl-xL, in LAN-5 and RT-BM-1, which were less sensitive to SINV infection, increased in response to SINV infection, while the other NB cell lines sensitive to SINV infection failed to respond. In nude mice, intratumoral and intravenous SINV inoculations caused significant regression of NB xenograft tumors. CONCLUSION: Our results suggested that SINV AR339 was significantly oncolytic against human NB. Thus, SINV showed promise as a novel therapy for treating NB.
Authors: S Goto; S Umehara; R B Gerbing; D O Stram; G M Brodeur; R C Seeger; J N Lukens; K K Matthay; H Shimada Journal: Cancer Date: 2001-11-15 Impact factor: 6.860
Authors: Michael P La Quaglia; Brian H Kushner; Wendy Su; Glenn Heller; Kim Kramer; Sara Abramson; Nancy Rosen; Suzanne Wolden; Nai-Kong V Cheung Journal: J Pediatr Surg Date: 2004-03 Impact factor: 2.545
Authors: Jen-Chieh Tseng; Brandi Levin; Alicia Hurtado; Herman Yee; Ignacio Perez de Castro; Maria Jimenez; Peter Shamamian; Ruzhong Jin; Richard P Novick; Angel Pellicer; Daniel Meruelo Journal: Nat Biotechnol Date: 2003-11-30 Impact factor: 54.908